2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

Purpose: This study investigates the efficacy and safety of anlotinib in combination with PD-1 monoclonal antibody across different dosing regimens for advanced non-small cell lung cancer (NSCLC). It aims to determine whether a medium dosage provides the best therapeutic outcomes.

Methods: A retrospective analysis was conducted on NSCLC patients treated between July 2018 and December 2022 at The First Affiliated Hospital of Chongqing Medical University. Patients were categorized into three dosage groups: low (8 mg/day), medium (10 mg/day), and high (12 mg/day), each combined with 200 mg of PD-1 monoclonal antibody. Treatment cycles were administered every 21 days. Primary endpoints was Overall Survival (OS), while secondary endpoints assessed Objective Response Rate (ORR), Disease Control Rate (DCR), and quality of life, measured using the EORTC QLQ-C30 questionnaire.

Results: Median OS significantly varied across groups: 10.2 months (low), 21.3 months (medium), and 18.2 months (high). The medium-dose cohort exhibited the highest ORR and DCR, coupled with significant QoL enhancements in fatigue, appetite, and respiratory symptoms. Adverse events increased dose-dependently, with severe events reported in 6%, 8%, and 11% of low, medium, and high groups, respectively.

Conclusion: Medium-dose anlotinib combined with PD-1 therapy delivers superior survival and QoL outcomes with manageable toxicity. These results underscore its potential as an optimal treatment strategy for advanced NSCLC.